

Out. number: 194-00-40/04.07.2024 r.

**Publication of materials for holding a Extraordinary General Meeting of Shareholders of
"Sopharma" AD, scheduled for August 9, 2024**

Sofia, Bulgaria, July 4, 2024 - According to the requirements of Art. 100t of the Law on Public Offering of Securities the Board of directors of **"Sopharma" AD** (SFA: "BSE" AD, SPH: Warsaw Stock Exchange) presents the following materials on the agenda of AGM convened for August 9, 2024 to the attention of shareholders, which will be available on the website of Extri News (www.x3news.com), in the FSC system, on the Company's website <https://www.sopharmagroup.com/bg/investitori/obshcho-sbranie-na-akcionerite> and on the website www.investor.bg, as well as in hard copy at the address of the Company:

1. Minutes of a meeting of the Board of Directors for convening an Extraordinary Meeting of Shareholders of "Sopharma" AD;
2. Invitation to convene the Extraordinary Meeting of Shareholders (EGM) of "Sopharma" AD;
3. Power of attorney – an example for representing a shareholder at the EGM;
4. Declaration for voting by correspondence – an example for the EGM;
5. **For item 2 of the agenda:** Agreement for transformation through the merger of "Veta Pharma" AD into "Sopharma" AD, concluded on January 16, 2024, of Additional Agreement No. 1 of March 8, 2024. and of Additional Agreement No. 2 dated April 26, 2024 to it ("Conversion Agreement").
6. **For item 3 the agenda:** Report of the Board of Directors of "Sopharma" AD under Art. 262i of the Commercial Law to the shareholders of the Company regarding the transformation by merger of "Veta Pharma" AD into "Sopharma" AD.
7. **For item 4 of the agenda:** Inspector's report under Art. 262m of the Commercial Law regarding the transformation through the merger of "Veta Pharma" AD into "Sopharma" AD.

Pelagia Viatcheva

Investor Relations Director

Information about the company

Sopharma AD

Sopharma AD | 16 Iliensko Shose Str. | 1220 Sofia, Bulgaria | tel: +35928134200 | fax: +35929360286 | mail@sopharma.bg
sopharmagroup.com

This document is a translation of the original text in Bulgarian, in case of divergence the Bulgarian original is prevailing.



90 years of tradition and modernity - contemporary production, European standards and quality, best practices in the field of corporate and social responsibility.

Sopharma AD is the most successful Bulgarian company after the privatization, as from 2000 to today, the company realized 10 times growth in market capitalization and 25 times revenue growth. Over the past 10 years, Sopharma AD has been a leader in the pharmaceutical sector in Bulgaria.

Sopharma AD produces active substances and medicinal products; conducts activities related to development and implementation in the field of phytochemistry, chemistry and pharmacy, provides services related to production and other.

With 9 pharmaceutical plants in the country and the only ampoule factory in Bulgaria the company produces 3 billion tablets, 20 million syrup forms, has an authorization for over 200 generic products, 15 traditional products, 12 of which are plant-based, and uses more than 1500 tons of medicinal plants in its products.

Sopharma AD has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma AD is constantly investing in new technologies, innovations and research. The company maintains a dialogue with all players in the pharmaceutical industry and strives to contribute to improving the healthcare sector.

Sopharma Group

Sopharma Group is a vertically integrated healthcare business that operates in important health related sectors such as pharmaceuticals, hospital supplies, pharmaceutical products distribution and many others.